FDA Approves Monthly Lung Cancer Shot, Easing Patient Burden

HORSHAM, PA – February 17, 2026 – The U.S. Food and Drug Administration (FDA) has approved a new monthly dosing schedule for Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), a move that significantly eases the treatment burden for patients with a common form of advanced lung cancer. The approval makes it the only targeted therapy for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) that can be administered just once a month.

This landmark decision, announced today, allows patients receiving the therapy in combination with the oral drug LAZCLUZE® (lazertinib) to transition from initial weekly injections to a less frequent monthly schedule as early as their fifth week of treatment. The change promises to dramatically reduce clinic visits without compromising the drug's established efficacy and safety, marking a pivotal moment in patient-centric cancer care.

A New Era of Convenience for Patients

For individuals battling advanced NSCLC, treatment often involves a grueling schedule of hospital visits that can dominate their lives. The recent approval of the subcutaneous formulation of RYBREVANT FASPRO™ had already transformed the patient experience by cutting administration time from hours-long intravenous infusions to a simple injection that takes minutes. Today's approval builds on that progress, offering a new level of freedom and flexibility.

The shift to monthly dosing is supported by data showing it delivers consistent outcomes comparable to the previous bi-weekly schedule. This means patients can spend less time in infusion centers and more time focusing on their lives, families, and well-being.

"A monthly dosing schedule offers patients convenience without sacrificing efficacy," said Danny Nguyen, M.D., Assistant Clinical Professor at City of Hope and a principal investigator for the drug's clinical trials. "With a flexible schedule that reduces time in the clinic, patients may be able to stay on therapy longer and free up time to focus on the moments that matter most."

Beyond convenience, the subcutaneous formulation has also demonstrated a significant safety advantage. Data from clinical studies show a fivefold reduction in administration-related reactions (ARRs) compared to the historical intravenous delivery, with rates for the monthly schedule (12%) remaining consistent with the bi-weekly subcutaneous option (13%).

Reshaping the Competitive Oncology Market

This approval strategically positions Johnson & Johnson in the highly competitive market for EGFR-mutated lung cancer therapies. The first-line treatment space has been largely dominated by daily oral medications like AstraZeneca's osimertinib (Tagrisso®). While effective, these therapies face challenges, including the eventual development of drug resistance.

RYBREVANT®, in combination with LAZCLUZE®, offers a different mechanism of action. As a bispecific antibody, it targets both EGFR and MET pathways, a dual-pronged attack designed to overcome and delay resistance. The pivotal MARIPOSA study demonstrated that this combination provided a statistically significant improvement in progression-free survival compared to osimertinib, with a median of 23.7 months versus 16.6 months.

By adding the unparalleled convenience of a once-monthly injection to this powerful efficacy profile, Johnson & Johnson is creating a compelling new value proposition. The company is now competing not only on clinical outcomes but also on quality of life, a factor of increasing importance to patients and oncologists. This unique combination of power and convenience could drive significant adoption and reshape treatment standards for thousands of patients diagnosed with this form of lung cancer each year.

The Science Behind the Shift

The innovation behind RYBREVANT FASPRO™ lies in both its biological design and its advanced delivery method. Amivantamab, the active drug, is a first-in-class bispecific antibody. Unlike traditional monoclonal antibodies that hit a single target, it is engineered to bind to two distinct sites: the EGFR and the MET receptor on cancer cells. This dual targeting is crucial, as MET amplification is a known mechanism of resistance to EGFR-inhibiting drugs. By blocking both pathways simultaneously, the therapy aims to deliver a more durable response.

This potent antibody is paired with LAZCLUZE®, a third-generation EGFR tyrosine kinase inhibitor (TKI) that also targets the cancer-driving mutations from within the cell. The combination provides a comprehensive blockade of the tumor's primary growth signals.

The ability to deliver this complex biologic via a simple subcutaneous injection is enabled by Halozyme's ENHANZE® drug delivery technology. The formulation includes a synthetic version of a human enzyme, hyaluronidase, which temporarily breaks down a component of the tissue under the skin. This allows for the rapid dispersion and absorption of a larger volume of medication than would typically be possible with a standard subcutaneous shot, paving the way for a quick, under-the-skin administration that replaces a lengthy IV drip.

A Foundation of Robust Clinical Data

The FDA's decision is anchored in solid clinical evidence. The approval for the monthly schedule was supported by data from the PALOMA-2 study, which demonstrated a high objective response rate and confirmed that drug concentrations in the blood remained consistent with the more frequent bi-weekly dosing. The study also reinforced the favorable safety profile, showing no new safety signals with the less frequent administration.

While offering greater convenience, the therapy's safety profile requires careful management. The prescribing information includes warnings for potential side effects, including dermatologic reactions, ocular toxicity, and a risk of interstitial lung disease (ILD)/pneumonitis. When combined with LAZCLUZE®, there is also an increased risk of venous thromboembolic events (VTEs), or blood clots, which has led to a recommendation for patients to receive prophylactic anticoagulation for the first four months of treatment.

Despite these risks, which are common in this class of potent cancer therapies, clinical data shows that the treatment is generally manageable. In the PALOMA-2 study, only 8% of patients discontinued amivantamab due to treatment-related adverse events. This new, more convenient dosing regimen represents a significant step forward in optimizing treatment, blending unmatched survival benefits with a simplified delivery that profoundly impacts the patient experience in the fight against advanced lung cancer.